hereditary angieoedema

Biotech

Pharvaris runs tox test to reverse clinical hold for HAE asset

Pharvaris' PHA121 will undergo a six-month animal toxicity trial aimed at assuaging concerns over the med’s safety.
Ben Adams Jan 9, 2023 10:42am

Catabasis Pharmaceuticals no more: Meet Astria Therapeutics

Sep 8, 2021 9:00am

KalVista hit with a clinical hold on 2nd asset

Apr 20, 2021 8:05am

Ionis' antisense drug curbs HAE attacks in phase 2

Mar 29, 2021 9:55am

Pharvaris nabs Shire exec as new CMO

Feb 7, 2020 9:22am

Pharvaris raises $66M to push oral HAE drug through the clinic

Sep 10, 2019 11:08am